<DOC>
	<DOCNO>NCT00506597</DOCNO>
	<brief_summary>The goal clinical research study allow doctor use Erwinia L-Asparaginase ( Erwinase® ) replacement patient allergic E.coli L-asparaginase Pegylated E.coli L-asparaginase part treatment acute lymphoblastic leukemia ( ALL ) T B cell lymphoma . This trial part multi institutional effort drug company make Erwinase available use .</brief_summary>
	<brief_title>Erwinase Study Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The Study Drug : Erwinia L-Asparaginase help stop growth cancer cell block nutrient cancer cell need survive . Study Visits : Erwinia L-Asparaginase give either outpatient inpatient , depend upon condition . If allergic E. Coli Asparaginase Pegylated Asparaginase , give 6 dos every day . You receive Erwinia L-Asparaginase injection needle vein , skin , muscle , direct study doctor . You monitor closely nurse doctor , , receive drug side effect . If develop severe allergy Erwinia L-Asparaginase , may receive asparaginase therapy . The length study base upon ALL treatment currently receive . Your doctor discus detail treatment schedule . This investigational study . Erwinia L-Asparaginase FDA approve . The FDA allow patient acute lymphoblastic leukemia allergic reaction U.S.-approved L-asparaginases receive Erwinia L-Asparaginase . Up 35 patient take part study The University Texas ( UT ) MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>1 . Age : restriction 2 . Patient must give write informed consent receive Erwinase® Investigational New Drug ( IND ) 290 . 3 . Patient must treat Acute Lymphoblastic Leukemia 4 . Patient either T B cell lymphoma treat Asparaginase . 5 . Patient must either systemic hypersensitivity reaction native ( Elspar® ) pegylated ( Oncaspar® ) E. coli LAsparaginase . This include patient generalized rash without anaphylactic symptom , local pain redness site injection . 6 . Patient previously document local systemic reaction E. coli derive LAsparaginase . 7 . Patients Elspar® ( include enrol clinical trial randomize Elspar® ) Elspar® available . 1 . Previous allergic reaction Erwinia LAsparaginase ( Erwinase ® ) 2 . Previous acute pancreatitis 3 . Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Erwinia L-Asparaginase</keyword>
	<keyword>Erwinase</keyword>
</DOC>